403 related articles for article (PubMed ID: 30591082)
1. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
2. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
[TBL] [Abstract][Full Text] [Related]
3. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
4. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological characteristics of renal cell carcinomas with MiTF translocation.
Filler T; Verkarre V; Peyrottes A; Poinard F; Lupo A; Dariane C; Hurel S; Timsit MO; Mejean A; Audenet F
Fr J Urol; 2024 Mar; 34(2):102569. PubMed ID: 38717457
[TBL] [Abstract][Full Text] [Related]
7. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
8. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH.
Xia QY; Wang XT; Ye SB; Wang X; Li R; Shi SS; Fang R; Zhang RS; Ma HH; Lu ZF; Shen Q; Bao W; Zhou XJ; Rao Q
Histopathology; 2018 Apr; 72(5):786-794. PubMed ID: 29148086
[TBL] [Abstract][Full Text] [Related]
9. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
10. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
Geller JI; Argani P; Adeniran A; Hampton E; De Marzo A; Hicks J; Collins MH
Cancer; 2008 Apr; 112(7):1607-16. PubMed ID: 18278810
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
12. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
13. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Négrier S; Campedel L; Martini D; Borchiellini D; Chahoud J; Lodi M; Barthélémy P; Hasanov E; Hahn AW; Gil T; Viswanathan SR; Bakouny Z; Msaouel P; Asim Bilen M; Choueiri TK; Albiges L; Tannir NM; Malouf GG
Oncologist; 2022 Dec; 27(12):1041-1047. PubMed ID: 35979929
[TBL] [Abstract][Full Text] [Related]
15. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.
Ramphal R; Pappo A; Zielenska M; Grant R; Ngan BY
Am J Clin Pathol; 2006 Sep; 126(3):349-64. PubMed ID: 16880148
[TBL] [Abstract][Full Text] [Related]
16. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Alhalabi O; Thouvenin J; Négrier S; Vano YA; Campedel L; Hasanov E; Bakouny Z; Hahn AW; Bilen MA; Msaouel P; Choueiri TK; Viswanathan SR; Sircar K; Albiges L; Malouf GG; Tannir NM
Oncologist; 2023 May; 28(5):433-439. PubMed ID: 36640141
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
